IPO
The company’s Luye Medical Group unit plans to evaluate proposals from investment banks as soon as next month, according to the people.
The company believes its ultrasensitive immunoassay technology is well-suited to pharma research.
resTORbio is developing novel therapies to improve immune function in the elderly.
The Suzhou-based cancer-drug maker has been discussing a valuation of more than $1 billion.
The company plans to offer 2.73 million shares priced between $10 and $12 each.
The listing of a minority of the unit, which makes X-ray and MRI machines, is set to take place in the first half of 2018.
Three biotech companies want to start out the new year with a new start.
A look at what three ex-Genentech employees have accomplished at Denali so far.
With the raise, the company’s market valuation is currently $1.7B.
Siemens Healthineers, the German industrial conglomerate’s largest and most profitable division, is worth roughly $47.49 billion.
PRESS RELEASES